In a previous study conducted by the University of California Lung Cancer Consortium, 54.9% of patients had EGFR mutations, 32.9% of patients had KRAS mutations, 5.3% of patients had ALK fusions, and < 3% of patients had other mutations (HER2, MET, RET, ROS1, or BRAF-non-V600E). Here, ERBB2 is linked to lung carcinoma.